Physician profile
Robert C Weber
NPI 1184656340
$2,959.58
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $954 · 2020: $421 · 2021: $897 · 2022: $582 · 2023: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $104.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $833.26 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $418.97 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $334.84 | 2019-2022 | |
| Abbvie INC. | $224.92 | 2022-2023 | Lumigan, Vuity, Alphagan P |
| Sun Pharmaceutical Industries INC. | $181.46 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $175.25 | 2019-2021 | |
| Alcon Vision LLC | $146.39 | 2021-2022 | |
| Glaukos Corporation | $128.55 | 2019 | |
| Alexion Pharmaceuticals, INC. | $124.74 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $100.63 | 2019-2021 | |
| Sight Sciences, INC. | $93.92 | 2019 | |
| Ocular Therapeutix, INC. | $67.87 | 2019-2023 | Dextenza |
| Omeros Corporation | $46.92 | 2020-2021 | |
| Rayner Intraocular Lenses Limited | $37.14 | 2022-2023 | Rayone Aspheric, Omidria, Rayone Emv |
| Bausch & Lomb Americas INC. | $17.94 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $15.55 | 2019 | |
| Eyepoint US, INC. | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.